Generic drug entry prior to patent expiration an FTC study
Author:
Publisher: DIANE Publishing
Published: 2002
Total Pages: 129
ISBN-13: 1428951938
DOWNLOAD EBOOKRead and Download eBook Full
Author:
Publisher: DIANE Publishing
Published: 2002
Total Pages: 129
ISBN-13: 1428951938
DOWNLOAD EBOOKAuthor:
Publisher: U.S. Government Printing Office
Published: 1998
Total Pages: 94
ISBN-13:
DOWNLOAD EBOOKAuthor: Robin Feldman
Publisher: Cambridge University Press
Published: 2017-06-09
Total Pages: 165
ISBN-13: 131673949X
DOWNLOAD EBOOKWhile the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.
Author: Michael Kremer
Publisher:
Published: 1996
Total Pages: 56
ISBN-13:
DOWNLOAD EBOOKAuthor: Kenneth L. Dorsney
Publisher: American Bar Association
Published: 2012
Total Pages: 0
ISBN-13: 9781614384786
DOWNLOAD EBOOKExamining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals and U.S. patent law in the context of Paragraph IV ANDA litigation, this comprehensive guide focuses on current and developing law as well as litigation strategies and tactics. This ready roadmap begins with an explanation of the Hatch-Waxman Act, its implementation, and litigation. Other topics include preparing and trying the case, post-trial issues and appeals, remedies, settlement, antitrust implications, and litigation of pharmaceuticals outside the U.S.
Author: United States. Federal Trade Commission
Publisher:
Published: 2002
Total Pages: 136
ISBN-13:
DOWNLOAD EBOOKAuthor: Neil P. DiSpirito
Publisher:
Published: 2016-10-13
Total Pages: 804
ISBN-13: 9781935065753
DOWNLOAD EBOOKAuthor:
Publisher:
Published: 1981
Total Pages: 88
ISBN-13:
DOWNLOAD EBOOKAuthor: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Published: 2017-09-28
Total Pages: 483
ISBN-13: 0309459575
DOWNLOAD EBOOKDrug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author: Institute of Medicine
Publisher: National Academies Press
Published: 2011-04-03
Total Pages: 442
ISBN-13: 0309158060
DOWNLOAD EBOOKRare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.